Regulatorische Updates

Korea Korus was ordered to halt production of its export‑only recombinant human erythropoietin product for one month after failing to conduct required post‑marketing safety studies.

The Korea Pharmaceutical & Bio Association will hold a seminar on Sep 30 to discuss 2026 accounting issues and response strategies for pharma‑bio firms, featuring Samjeong KPMG executives.

Ahead of a national audit, the Seoul City Pharmacists Association urged the National Assembly to prioritize patient safety and strengthen oversight before expanding telemedicine drug delivery and safety‑standby medicines.

A grade‑5 NHIS staff accessed family and others’ personal data 62 times between Dec 2020 and Nov 2023; a three‑month suspension was imposed in May 2024.

The Korean Pharmaceutical Association will host a large rally on June 20 in Gwanghwamun, uniting pharmacists and pharmacy students to oppose the government's telemedicine and prescription‑delivery expansion, while also raising concerns about platform‑driven medical commercialization and health‑insurance financing.

On September 14, 2026, the Ministry of Health and Welfare announced the appointment of Lee Su-wan to the position of Section Chief in the Disability Independence Division.

The Ministry of Health and Welfare announced plans to create a dedicated permanent organization to tackle abnormal fake medical treatments, including fee paybacks and advance high‑cost payments.

Expectations for swift pharmacy‑related bill discussions after the National Assembly session have faded as partisan fights over a Justice Minister nominee dominate committees.

Policy director Jeon Jin‑han cautions that the government's plan to broaden medication delivery for telemedicine patients could increase private platform control and push medical privatization.

The Korean Ministry of Food and Drug Safety inspected the pilot K‑NASS system, aiming to detect misuse and illegal distribution of medical narcotics more rapidly.

KDCA announced a 2026‑2027 influenza epidemic warning on Sep 11, citing rapid rise in cases among school‑age children and infants and urging preventive measures in group settings.

The Korean Pharmaceutical Association calls for dropping in‑hospital compounding of abortion induction drugs and pushing for health‑insurance reimbursement, warning against utilization barriers.